Read the full guides
Orforglipron
Last reviewed: August 16, 2026 by The Peptide Catalog Team
The first FDA-approved oral GLP-1 pill — a daily tablet with ~12% weight loss in trials, no injections. The first FDA-approved oral GLP-1 pill — a once-daily tablet (no injection, no reconstitution) with ~12% weight loss in Phase 3 trials.
Overview
Core Benefits
Key AdvantagesThese are educational summaries of commonly discussed effects in wellness/regenerative contexts, not guarantees.
Orforglipron Results Timeline
ProgressionTimeline is illustrative and non-guaranteed. Outcomes vary and are commonly discussed alongside training, nutrition, sleep, and cycling practices.
How It WorksOral Small-Molecule GLP-1 Receptor Agonist
Receptor → Metabolic Cascade → Weight & Glucose → Outcomes
GLP-1 Receptor — Single Activation, Oral Route
Orforglipron is a non-peptide small molecule that activates the GLP-1 receptor — the same target as injectable GLP-1 agonists, but reached by a once-daily oral tablet. As a single (mono) agonist it does not touch the GIP or glucagon receptors, unlike the injectable dual tirzepatide or triple retatrutide.
GLP-1 cAMP Signaling → Appetite Suppression + Insulin Secretion
GLP-1 receptor activation raises intracellular cAMP, suppressing appetite, slowing gastric emptying, and stimulating glucose-dependent insulin release. Because it is a chemically synthesized small molecule, oral bioavailability of roughly 30-40% and a ~24-38 hour half-life support once-daily dosing — with no food or water timing restriction, unlike oral semaglutide.
Reduced Intake → Weight Loss and Glucose Control
In the Phase 3 ATTAIN-1 trial (72 weeks), the 36mg dose produced about 12.4% mean body-weight loss versus placebo; A1c fell roughly 1.5-1.6% in early type 2 diabetes (ACHIEVE-1). This lands below injectable tirzepatide (~21%) and retatrutide (~24%) — consistent with single-receptor versus dual/triple agonism.
Appetite Reduction with Titration-Related GI Effects
Reduced appetite and gradual weight loss over months, taken as one daily pill with no injection or reconstitution. Gastrointestinal effects (nausea, vomiting, diarrhea, constipation) are the most common, dose-dependent, and typically transient during titration.
What Makes This Peptide Different
Orforglipron's distinction is format, not peak efficacy. It is the first oral small-molecule GLP-1 agonist approved (2026, as Foundayo) for chronic weight management — a once-daily tablet with no food or water timing restriction. Being chemically synthesized rather than a manufactured peptide, it avoids the cold-chain and injectable-fill constraints of injectable agonists, which favors manufacturing scale. Its trial weight loss (~12%) sits below injectable tirzepatide and retatrutide; the trade-off is oral convenience and access, not the largest reduction.
Orforglipron Vendors
Dosing ProtocolWeight Loss (Oral GLP-1)
Educational reference only. Individual responses vary. Consult healthcare provider before use.
Why This Dosing Protocol
Why gradual titration? As with other GLP-1 agonists, GI side effects are minimized by starting low and stepping up slowly. Trials titrated over several weeks; the approved tablet starts at a low daily dose and increases at intervals of at least 30 days toward its labeled maximum.
Reconstitution Calculator
Dilution math and unit conversions. Prefilled using a common vial size for this peptide.
Open calculatorStorage & Handling
Storage at a glance
Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.
Handling specifics
Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.
- Freezer (-20°C): 1+ year
- Refrigerator (2-8°C): 1-3 months
- Room temperature: 2-3 weeks (emergency only)
- MUST refrigerate at 2-8°C
- 4-week maximum shelf life
- NEVER freeze after reconstitution
- Use bacteriostatic water for multi-dose
FAQ
How is orforglipron different from tirzepatide and retatrutide?
Orforglipron is a once-daily oral pill and a single GLP-1 receptor agonist — it activates only the GLP-1 receptor. Tirzepatide is an injectable dual GLP-1/GIP agonist, and retatrutide is an injectable triple GLP-1/GIP/glucagon agonist. The trade-off is convenience versus peak effect: orforglipron's trial weight loss (~12%) sits below tirzepatide (~21%) and retatrutide (~24%), but it requires no injection.
Is orforglipron FDA approved?
Yes. The FDA approved orforglipron in April 2026 under the brand name Foundayo for chronic weight management in adults with obesity, or overweight plus a weight-related condition. It is made by Eli Lilly. A separate type 2 diabetes indication was filed but is not approved as of this writing.
How much weight did people lose in the trials?
In the Phase 3 ATTAIN-1 trial (72 weeks), participants on the 36mg dose lost about 12.4% of body weight on average, versus 0.9% on placebo. Lower doses lost less — roughly 7.8% at 6mg and 9.3% at 12mg. About 40% of the top-dose group lost at least 15% of their weight.
Is orforglipron a pill or an injection?
A pill. Orforglipron is a once-daily oral tablet — no injection, no reconstitution, and no requirement to take it fasting or with a specific amount of water. That oral, small-molecule design is its main practical advantage over injectable GLP-1 agonists.
What are the side effects?
The most common are gastrointestinal — nausea, vomiting, diarrhea, and constipation. They are dose-dependent and tend to be worst during dose escalation, then ease. In the ATTAIN-1 trial, discontinuation for side effects rose with dose, up to about 10% at the highest dose.
How does its blood-sugar effect compare?
In early type 2 diabetes (the ACHIEVE-1 trial), orforglipron lowered A1c by roughly 1.5-1.6%. That is meaningful but below injectable tirzepatide (around 2.3% in its trials). The type 2 diabetes indication remains under FDA review; orforglipron is currently approved for weight management.
How long does reconstituted peptide last?
Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide.
Is this peptide legal to purchase?
Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use.
New to peptides?
Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.
Orforglipron Research Articles
Orforglipron Dosing: 0.8mg Oral Titration
The label starts orforglipron at 0.8mg once daily and steps up monthly to 17.2mg -- but Phase 3 trials used 6, 12 and 36mg. How the oral GLP-1 is dosed.
clinicalWhat Is Orforglipron (Foundayo)? Oral GLP-1 Pill
Orforglipron is the first oral GLP-1 pill, FDA-approved as Foundayo in 2026. How the once-daily tablet works, and why its weight loss trails injections.
comparisonOrforglipron vs Tirzepatide: Pill or Shot?
Orforglipron is a daily pill, tirzepatide a weekly shot — but trials show the injection lost nearly twice the weight. The honest tradeoff, side by side.
comparisonOrforglipron vs Retatrutide: Pill vs Injection
One's an FDA-approved pill; the other an injectable that hit 24% in trials. Oral scale vs peak power — the honest cross-trial comparison.
Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.